Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1996 Nov;75(5):436–439. doi: 10.1136/adc.75.5.436

Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome.

J Litzman 1, A Jones 1, I Hann 1, H Chapel 1, S Strobel 1, G Morgan 1
PMCID: PMC1511781  PMID: 8957959

Abstract

AIM: To assess the results of supportive treatment with intravenous immunoglobulin (IVIG) and antibiotic prophylaxis in combination with splenectomy in patients with Wiskott-Aldrich syndrome. STUDY DESIGN: Retrospective review of case records of 21 patients from March 1984 to February 1996. RESULTS: Thrombocytopenia was cured in 14 of 15 patients who had splenectomy, but it recurred intermittently in three. Mean platelet volume (MPV) was normal transiently in some patients, but all MPV values were subnormal 8-23 months after splenectomy. Antibiotic and IVIG prophylaxis may have contributed to the lack of a detectable increase in the number of severe acute bacterial infections in the 451 months after splenectomy. Four patients died in 2205 months of observation before and after splenectomy (median 82, range 16-248): two of cerebral B cell lymphoma, one of progressive multifocal leucoencephalopathy, and one with severe chronic chest disease of pneumonia. CONCLUSION: Adequate supportive treatment with IVIG and antibiotic prophylaxis together with splenectomy enables good survival and quality of life in the short and medium term in patients with Wiskott-Aldrich syndrome. Persistence of infection, bleeding, and vasculitic and allergic symptoms in a significant minority and the risk of development of lymphoma, however, suggest that bone marrow transplantation may be indicated if an HLA identical donor is available.

Full text

PDF
437

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blaese R. M., Strober W., Brown R. S., Waldmann T. A. The Wiskott-Aldrich syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet. 1968 May 18;1(7551):1056–1061. doi: 10.1016/s0140-6736(68)91411-6. [DOI] [PubMed] [Google Scholar]
  2. Brochstein J. A., Gillio A. P., Ruggiero M., Kernan N. A., Emanuel D., Laver J., Small T., O'Reilly R. J. Marrow transplantation from human leukocyte antigen-identical or haploidentical donors for correction of Wiskott-Aldrich syndrome. J Pediatr. 1991 Dec;119(6):907–912. doi: 10.1016/s0022-3476(05)83041-0. [DOI] [PubMed] [Google Scholar]
  3. Cooper M. D., Chae H. P., Lowman J. T., Krivit W., Good R. A. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med. 1968 Apr;44(4):499–513. doi: 10.1016/0002-9343(68)90051-x. [DOI] [PubMed] [Google Scholar]
  4. Corash L., Shafer B., Blaese R. M. Platelet-associated immunoglobulin, platelet size, and the effect of splenectomy in the Wiskott-Aldrich syndrome. Blood. 1985 Jun;65(6):1439–1443. [PubMed] [Google Scholar]
  5. Derry J. M., Ochs H. D., Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell. 1994 Aug 26;78(4):635–644. doi: 10.1016/0092-8674(94)90528-2. [DOI] [PubMed] [Google Scholar]
  6. Fischer A., Landais P., Friedrich W., Gerritsen B., Fasth A., Porta F., Vellodi A., Benkerrou M., Jais J. P., Cavazzana-Calvo M. Bone marrow transplantation (BMT) in Europe for primary immunodeficiencies other than severe combined immunodeficiency: a report from the European Group for BMT and the European Group for Immunodeficiency. Blood. 1994 Feb 15;83(4):1149–1154. [PubMed] [Google Scholar]
  7. Gröttum K. A., Hovig T., Holmsen H., Abrahamsen A. F., Jeremic M., Seip M. Wiskott-Aldrich syndrome: qualitative platelet defects and short platelet survival. Br J Haematol. 1969 Oct;17(4):373–388. doi: 10.1111/j.1365-2141.1969.tb01383.x. [DOI] [PubMed] [Google Scholar]
  8. Kuramoto A., Steiner M., Baldini M. G. Lack of platelet response to stimulation in the Wiskott-Aldrich syndrome. N Engl J Med. 1970 Feb 26;282(9):475–479. doi: 10.1056/NEJM197002262820904. [DOI] [PubMed] [Google Scholar]
  9. Lenarsky C., Weinberg K., Kohn D. B., Parkman R. Unrelated donor BMT for Wiskott-Aldrich syndrome. Bone Marrow Transplant. 1993 Aug;12(2):145–147. [PubMed] [Google Scholar]
  10. Lum L. G., Tubergen D. G., Corash L., Blaese R. M. Splenectomy in the management of the thrombocytopenia of the Wiskott-Aldrich syndrome. N Engl J Med. 1980 Apr 17;302(16):892–896. doi: 10.1056/NEJM198004173021604. [DOI] [PubMed] [Google Scholar]
  11. Marone G., Albini F., di Martino L., Quattrin S., Poto S., Condorelli M. The Wiskott-Aldrich syndrome: studies of platelets, basophils and polymorphonuclear leucocytes. Br J Haematol. 1986 Apr;62(4):737–745. doi: 10.1111/j.1365-2141.1986.tb04097.x. [DOI] [PubMed] [Google Scholar]
  12. Mathew P., Conley M. E. Effect of intravenous gammaglobulin (IVIG) on the platelet count in patients with Wiskott-Aldrich syndrome. Pediatr Allergy Immunol. 1995 May;6(2):91–94. doi: 10.1111/j.1399-3038.1995.tb00265.x. [DOI] [PubMed] [Google Scholar]
  13. Mullen C. A., Anderson K. D., Blaese R. M. Splenectomy and/or bone marrow transplantation in the management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood. 1993 Nov 15;82(10):2961–2966. [PubMed] [Google Scholar]
  14. Murphy S., Oski F. A., Naiman J. L., Lusch C. J., Goldberg S., Gardner F. H. Platelet size and kinetics in hereditary and acquired thrombocytopenia. N Engl J Med. 1972 Mar 9;286(10):499–504. doi: 10.1056/NEJM197203092861001. [DOI] [PubMed] [Google Scholar]
  15. Ochs H. D., Slichter S. J., Harker L. A., Von Behrens W. E., Clark R. A., Wedgwood R. J. The Wiskott-Aldrich syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980 Feb;55(2):243–252. [PubMed] [Google Scholar]
  16. Rimm I. J., Rappeport J. M. Bone marrow transplantation for the Wiskott-Aldrich syndrome. Long-term follow-up. Transplantation. 1990 Oct;50(4):617–620. doi: 10.1097/00007890-199010000-00018. [DOI] [PubMed] [Google Scholar]
  17. Standen G. R. Wiskott-Aldrich syndrome: new perspectives in pathogenesis and management. J R Coll Physicians Lond. 1988 Apr;22(2):80–83. [PMC free article] [PubMed] [Google Scholar]
  18. Sullivan K. E., Mullen C. A., Blaese R. M., Winkelstein J. A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994 Dec;125(6 Pt 1):876–885. doi: 10.1016/s0022-3476(05)82002-5. [DOI] [PubMed] [Google Scholar]
  19. Weiden P. L., Blaese R. M. Hereditary thrombocytopenia: relation to Wiskott-Aldrich syndrome with special reference to splenectomy. Report of a family and review of the literature. J Pediatr. 1972 Feb;80(2):226–234. doi: 10.1016/s0022-3476(72)80583-3. [DOI] [PubMed] [Google Scholar]
  20. Wodzinski M. A., Lilleyman J. S. High-dose immunoglobulin therapy of Wiskott-Aldrich syndrome. Pediatr Hematol Oncol. 1987;4(4):345–348. doi: 10.3109/08880018709141288. [DOI] [PubMed] [Google Scholar]
  21. de Martino M., Galli L., Azzari C., Zammarchi E., Vierucci A. Effect of different intravenous immunoglobulin regimens on hemorrhages, platelet numbers and volume in a child with Wiskott-Aldrich syndrome. Vox Sang. 1994;67(3):317–319. doi: 10.1111/j.1423-0410.1994.tb01260.x. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES